

Autism Spectrum Disorder

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT04049578 WP40877

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This was a Phase Ib, multicenter, open-label study in children 2-4 years old with autism spectrum disorder (ASD) to investigate the pharmacokinetics, safety, and tolerability of an oral dose of balovaptan once a day (QD). The study was to consist of a 6-week treatment period to evaluate the pharmacokinetics of balovaptan in 2 to 4 year old children followed by an optional extension period of 48 weeks.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT04049578 WP40877
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=2 Years & <= 4 Years

Healthy Volunteers
No
